Merz Pharma GmbH & Co. KgaA – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Merz Pharma GmbH & Co. KGaA - Product Pipeline Review - 2012" provides data on the Merz Pharma GmbH & Co. KGaA's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Merz Pharma GmbH & Co. KGaA's corporate website, SEC filings, investor presentations and featured press releases, both from Merz Pharma GmbH & Co. KGaA and industry-specific third party sources, put together by our team.
Scope
- Merz Pharma GmbH & Co. KGaA - Brief Merz Pharma GmbH & Co. KGaA overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Merz Pharma GmbH & Co. KGaA human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Merz Pharma GmbH & Co. KGaA with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Merz Pharma GmbH & Co. KGaA's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Merz Pharma GmbH & Co. KGaA's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Merz Pharma GmbH & Co. KGaA in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Merz Pharma GmbH & Co. KGaA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Merz Pharma GmbH & Co. KGaA.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Merz Pharma GmbH & Co. KGaA and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Merz Pharma GmbH & Co. KgaA Snapshot
Merz Pharma GmbH & Co. KgaA Overview
Key Information
Key Facts
Merz Pharma GmbH & Co. KgaA – Research and Development Overview
Key Therapeutic Areas
Merz Pharma GmbH & Co. KgaA – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Merz Pharma GmbH & Co. KgaA – Pipeline Products Glance
Merz Pharma GmbH & Co. KgaA – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Merz Pharma GmbH & Co. KgaA Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Merz Pharma GmbH & Co. KgaA – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Merz Pharma GmbH & Co. KgaA – Drug Profiles
MRZ-8456
Product Description
Mechanism of Action
R&D Progress
MRZ-99030
Product Description
Mechanism of Action
R&D Progress
MUS-92579
Product Description
Mechanism of Action
R&D Progress
neramexane mesylate
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxinA
Product Description
Mechanism of Action
R&D Progress
Merz Pharma GmbH & Co. KgaA – Pipeline Products by Route of Administration
Merz Pharma GmbH & Co. KgaA – Pipeline Products By Mechanism of Action
Merz Pharma GmbH & Co. KgaA – Recent Pipeline Updates
Merz Pharma GmbH & Co. KgaA - Dormant Projects
Merz Pharma GmbH & Co. KgaA – Company Statement
Merz Pharma GmbH & Co. KgaA – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Merz Pharma GmbH & Co. KgaA, Recent Developments
Merz Pharma GmbH & Co. KgaA- Press Release
Apr 23, 2012: Merz To Present Phase IV XEOMIN Data At 64th AAN Annual Meeting
Apr 17, 2012: Merz Pharma Canada Announces Health Canada Approval Of XEOMIN COSMETIC
Mar 15, 2012: US Court Restricts Sale Of Merz's Xeomin And Dermal Fillers In US
Mar 14, 2012: Merz Aesthetics And Merz Pharma Commit To Full Remediation Compliance In Allergan Lawsuit
Jan 04, 2012: Merz Pharmaceuticals Receives J-Code For Xeomin From Centers For Medicare And Medicaid Services
Financial Deals Landscape
Merz Pharma GmbH & Co. KgaA, Deals Summary
Merz Pharma GmbH & Co. KgaA, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Merz Pharma Acquires Cuvposa, Oral Solution
Licensing Agreements
Mylan Enters Into Licensing Agreement With Forest Labs And Merz Pharma
Acumen Pharma Enters Into Licensing Agreement With Merz Pharma
Merz Pharma Enters Into Licensing Agreement With Kyorin Pharma
DiaGenic Enters Into Licensing Agreement With Merz Pharma
Tel-Aviv University Enters Into Licensing Agreement With Merz Pharma
Acquisition
Merz Pharma Completes Acquisition Of BioForm Medical
Merz Pharma Acquires Pharma Investment Holding
Merz Pharma Acquires Denfleet Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Merz Pharma GmbH & Co. KgaA, Key Information
Merz Pharma GmbH & Co. KgaA, Key Facts
Merz Pharma GmbH & Co. KgaA – Pipeline by Indication, 2012
Merz Pharma GmbH & Co. KgaA – Pipeline by Stage of Development, 2012
Merz Pharma GmbH & Co. KgaA – Monotherapy Products in Pipeline, 2012
Merz Pharma GmbH & Co. KgaA – Phase III, 2012
Merz Pharma GmbH & Co. KgaA – Phase II, 2012
Merz Pharma GmbH & Co. KgaA – Phase I, 2012
Merz Pharma GmbH & Co. KgaA – Pre-Clinical, 2012
Merz Pharma GmbH & Co. KgaA – Discovery, 2012
Merz Pharma GmbH & Co. KgaA – Pipeline By Route of Administration, 2012
Merz Pharma GmbH & Co. KgaA – Pipeline Products By Mechanism of Action, 2012
Merz Pharma GmbH & Co. KgaA – Recent Pipeline Updates, 2012
Merz Pharma GmbH & Co. KgaA - Dormant Developmental Projects,2012
Merz Pharma GmbH & Co. KgaA, Subsidiaries
Merz Pharma GmbH & Co. KgaA, Deals Summary
Merz Pharma Acquires Cuvposa, Oral Solution
Mylan Enters Into Licensing Agreement With Forest Labs And Merz Pharma
Acumen Pharma Enters Into Licensing Agreement With Merz Pharma
Merz Pharma Enters Into Licensing Agreement With Kyorin Pharma
DiaGenic Enters Into Licensing Agreement With Merz Pharma
Tel-Aviv University Enters Into Licensing Agreement With Merz Pharma
Merz Pharma Completes Acquisition Of BioForm Medical
Merz Pharma Acquires Pharma Investment Holding
Merz Pharma Acquires Denfleet Pharma
List of Figures
Merz Pharma GmbH & Co. KgaA – Pipeline by Indication, 2012
Merz Pharma GmbH & Co. KgaA – Pipeline by Stage of Development, 2012
Merz Pharma GmbH & Co. KgaA – Monotherapy Products in Pipeline, 2012
Merz Pharma GmbH & Co. KgaA – Pipeline By Route of Administration, 2012
Merz Pharma GmbH & Co. KgaA - Pipeline Products By Mechanism of Action, 2012 22